Data analysis has led to the decision to introduce a combined cohort in the Phase 1 clinical trial. In this trial, ARV-393 will be paired with glofitamab to explore a chemotherapy-free methodology for treating diffuse large B-cell lymphoma (DLBCL). The combined cohort is set to commence in the year 2026.